Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Moving to Fingolimod From Natalizumab in Multiple Sclerosis: The ENIGM Is Not Solved.
Clinical profile and short-term outcomes of optic neuritis patients in India.
Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis.
Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in Spain.
[Ophthalmological Findings in Paediatric and Adolescent Multiple Sclerosis.]
FRACTALKINE GENE RECEPTOR POLYMORPHISM IN PATIENTS WITH MULTIPLE SCLEROSIS.
Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial.
Editorial comment.
Multiple sclerosis: Infertility treatment increases multiple sclerosis activity.
The Hygiene Theory Harnessing Helminths and Their Ova to Treat Autoimmunity.
Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation.
Multiple Sites of the Cleavage of 21- and 25-Mer Encephalytogenic Oligopeptides Corresponding to Human Myelin Basic Protein (MBP) by Specific Anti-MBP Antibodies from Patients with Systemic Lupus Erythematosus.
Correction: Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine.
Brain atrophy and lesion load in a large population of patients with multiple sclerosis.
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis.
Bee Venom Acupuncture Alleviates Experimental Autoimmune Encephalomyelitis by Upregulating Regulatory T Cells and Suppressing Th1 and Th17 Responses.
Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance.
Leuprolide Acetate, a GnRH Agonist, Improves Experimental Autoimmune Encephalomyelitis: A Possible Therapy for Multiple Sclerosis.
Matrix metalloproteinase-3 in the central nervous system: a look on the bright side.
High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-astrocyte interaction.
[Diagnosis of multiple sclerosis].
Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort.
Autoimmune disease: A role for new anti-viral therapies?
Validation of the Social Provisions Scale in People With Multiple Sclerosis.
Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.
Pages
« first
‹ previous
…
337
338
339
340
341
342
343
344
345
…
next ›
last »